US 9,808,485 B2
Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
Richard Maziarz, Portland, OR (US); Magdalena Kovacsovics, Portland, OR (US); Philip Streeter, Oregon City, OR (US); Robert Deans, Riverside, CA (US); and Wouter Van't Hof, Shaker Mts, OH (US)
Assigned to Athersys, Inc., Cleveland, OH (US); and Oregon Health And Science University, Portland, OR (US)
Filed by Richard Maziarz, Portland, OR (US); Magdalena Kovacsovics, Portland, OR (US); Philip Streeter, Oregon City, OR (US); Robert Deans, Riverside, CA (US); and Wouter Van't Hof, Shaker Mts, OH (US)
Filed on Jan. 6, 2012, as Appl. No. 13/345,036.
Application 13/345,036 is a continuation of application No. 11/269,736, filed on Nov. 9, 2005, granted, now 8,147,824.
Application 11/269,736 is a continuation in part of application No. 11/151,689, filed on Jun. 13, 2005, granted, now 8,075,881.
Application 11/151,689 is a continuation in part of application No. 10/963,444, filed on Oct. 11, 2004, abandoned.
Application 10/963,444 is a continuation in part of application No. 10/048,757, granted, now 7,015,037, previously published as PCT/US00/21387, filed on Aug. 4, 2000.
Application 10/963,444 is a continuation in part of application No. 10/467,963, granted, now 7,838,289, previously published as PCT/US02/04652, filed on Feb. 14, 2002.
Claims priority of provisional application 60/147,324, filed on Aug. 5, 1999.
Claims priority of provisional application 60/164,650, filed on Nov. 10, 1999.
Claims priority of provisional application 60/268,786, filed on Feb. 14, 2001.
Claims priority of provisional application 60/269,062, filed on Feb. 15, 2001.
Claims priority of provisional application 60/310,625, filed on Aug. 7, 2001.
Claims priority of provisional application 60/343,836, filed on Oct. 25, 2001.
Prior Publication US 2012/0135043 A1, May 31, 2012
Int. Cl. A61K 35/12 (2015.01); A61N 5/10 (2006.01); A61K 45/06 (2006.01); A61K 35/14 (2015.01); A61K 35/28 (2015.01); A61K 39/00 (2006.01); C12N 5/074 (2010.01)
CPC A61K 35/12 (2013.01) [A61K 35/14 (2013.01); A61K 35/28 (2013.01); A61K 39/001 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); C12N 5/0607 (2013.01); A61K 2035/122 (2013.01); A61K 2035/124 (2013.01)] 28 Claims
 
1. A method of treatment of diabetes in a subject, comprising: administering to a subject in need of treatment for diabetes—by an effective route and in an effective amount to treat diabetes, cells that: are not embryonic stem cells, embryonic germ cells, or germ cells; can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages; express telomerase; are allogeneic or xenogeneic to the subject; do not provoke a deleterious immune response in the subject; and are effective to treat diabetes in the subject,—wherein the cells are administered adjunctively to one or more other treatments, without also administering an immunosuppressive treatment adjunctively to treatment with the cells wherein the cells have not been genetically engineered to improve their immunomodulatory properties.